To observe the clinical efficacy and safety of GINA regimen and GINA regimen combined with oral Huaiqihuang granule in the treatment of children with bronchial asthma.

A randomized, single blind, multicenter, parallel controlled clinical trial wascarried out.A total of 1 128 patients with bronchial asthma in children were randomized into two groups.The observation group were treated with GINA regimen combined with oral Huaiqihuang granule.The GINA regimen treatment group was treated by GINA regimen.Clinical assessment and C-ACT scores was observed in first month, third month, sixth month after treatment.Clinical assessment included the times of upper respiratory tract infection occurrence, bronchitis and pneumonia, asthmatic attacks, application of emergency medicine, hospitalizations due to asthmatic.Drug adverse effect in the two groups was compared.

The times of upper respiratory tract infection, bronchitis and pneumonia, asthmatic was significantly decreased(P<0.05), and C-ACTscores were significantly higher(P<0.05) in the first month, the third month, and the sixth month after treatment.There were 16 cases of drug related adverse reactions.Seven cases were in observation group(n=7)(1.15%) and 9 cases in the GINA regimen treatment group(n=9)(1.73%). There was no significant difference of adverse effect between the two groups(P>0.05).

The treatment of bronchial asthma in children with GINA regimen combined with oral Huaiqihuang granule can significantly reduce the incidence of respiratory infections and the number of asthmatic attacks dramatically and safely improve clinical curative effect, asthma control.

Asthma; Huaiqihuang; Children; Randomized controlled trial; Multicenter study; C-ACT